191 related articles for article (PubMed ID: 15638051)
1. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
Allanore Y; Sellam J; Batteux F; Job Deslandre C; Weill B; Kahan A
Clin Exp Rheumatol; 2004; 22(6):756-8. PubMed ID: 15638051
[TBL] [Abstract][Full Text] [Related]
2. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate.
Sellam J; Allanore Y; Batteux F; Deslandre CJ; Weill B; Kahan A
Joint Bone Spine; 2005 Jan; 72(1):48-52. PubMed ID: 15681248
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
[TBL] [Abstract][Full Text] [Related]
6. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
7. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
8. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Ferraro-Peyret C; Coury F; Tebib JG; Bienvenu J; Fabien N
Arthritis Res Ther; 2004; 6(6):R535-43. PubMed ID: 15535831
[TBL] [Abstract][Full Text] [Related]
9. Induction of autoantibodies during prolonged treatment with infliximab.
Louis M; Rauch J; Armstrong M; Fitzcharles MA
J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
11. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
13. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
Kiely PD; Johnson DM
Rheumatology (Oxford); 2002 Jun; 41(6):631-7. PubMed ID: 12048288
[TBL] [Abstract][Full Text] [Related]
14. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
18. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis.
Godinho F; Godfrin B; El Mahou S; Navaux F; Zabraniecki L; Cantagrel A
Clin Exp Rheumatol; 2004; 22(3):328-30. PubMed ID: 15144127
[TBL] [Abstract][Full Text] [Related]
19. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
Bobbio-Pallavicini F; Alpini C; Caporali R; Avalle S; Bugatti S; Montecucco C
Arthritis Res Ther; 2004; 6(3):R264-72. PubMed ID: 15142273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]